You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

HIVandHepatitis.com
HIV and AIDS Topics
Top News Articles
 
FDA-approved Treatments 
Experimental Treatments
Women / Children
Metabolic Complications
Opportunistic Infections
 Google Custom Search
New Drug-resistant Tuberculosis Strains Could Become Widespread

The emergence of new forms of tuberculosis (TB) could significantly increase the proportion of drug-resistant cases globally, according to a recent study conducted by Australian researchers at the University of New South Wales and the University of Western Sydney. Results were published August 12, 2009 in the Proceedings of the National Academy of Sciences.

Chest X-ray image. One in three humans already carries the TB bacterium.
(Credit: Image courtesy of
University of New South Wales)
Although the overall incidence of TB is falling in some regions, the emergence of antibiotic resistance could lead to the widespread emergence of untreatable strains of the disease.

Following are edited excerpts from a review of the recent study published in Science Daily.

Laboratory-based studies have suggested that antibiotic-resistant TB strains cause longer-lasting infections, but with a lower transmission rate. Therefore, scientists have questioned whether drug-resistant TB strains are more likely than drug-sensitive strains to persist and spread -- an important question for predicting the future impact of the disease.

One in three people already carries the TB bacterium. Although it remains latent in most cases, the World Health Organization (WHO) has estimated there were 9.27 million new cases of TB in 2007. There were 1.6 million TB-related deaths in 2005. Drug-resistant TB is caused by inconsistent or partial treatment, when patients do not take all their medicines regularly for the required period or because the drug supply is unreliable.

A research team led by University of New South Wales' Dr. Mark Tanaka used epidemiological and molecular data from Mycobacterium tuberculosis strains isolated from Cuba, Estonia, and Venezuela to estimate the rate of evolution of drug resistance and to compare the relative "reproductive fitness" of resistant and drug-sensitive strains.

"We found that the overall fitness of drug-resistant strains is comparable to drug-sensitive strains," said Dr. Tanaka of the Evolution and Ecology Research Centre. "This was especially so in Cuba and Estonia, where the there is a high prevalence of drug-resistant cases."

The finding may reflect an inconsistency in drug treatment programs in these countries. Indeed, Estonia now has one of the highest rates of multi-drug resistant TB in the world. The intermittent presence of drugs and the resulting transmission of resistant strains would have let drug-resistant strains collectively spend more time within untreated hosts, allowing them to evolve ways to become more infectious and out-compete the drug-sensitive strains.

The study also reveals that the contribution of transmission to the spread of drug resistance is very high -- up to 99% -- compared with acquired resistance due to treatment failure. "Our results imply that drug-resistant strains of TB are likely to become highly prevalent in the next few decades," said UNSW's Dr. Fabio Luciani, the study's lead author. "They also suggest that limiting further transmission of TB might be an effective approach to reducing the impact of drug resistance."

"Mathematical and statistical methods can add a lot of value to empirical data by allowing us to account for the processes behind them," said research co-author, Dr Andrew Francis from the University of Western Sydney. "In this case, we use samples of TB genotypes, together with information about drug resistance, to make inferences and predictions that wouldn't have been possible just a few years ago."

About Tuberculosis
Tuberculosis is a contagious disease. Like the common cold, it spreads through the air. Only people who are sick with TB in their lungs are infectious. When infectious people cough, sneeze, talk or spit, they propel TB germs, known as bacilli, into the air. A person needs only to inhale a small number of these to be infected.

Left untreated, each person with active TB disease will infect on average between 10 and 15 people every year. However, people infected with TB bacilli will not necessarily become sick with the disease. The immune system "walls off" the TB bacilli and it can lie dormant for years. When someone's immune system is weakened, however, the chances of becoming sick are greater.

Until 50 years ago, there were no medications to cure TB. Now, strains that are resistant to antibiotics have emerged and about 1.7% of cases worldwide have multidrug-resistant disease (MDR-TB). In 2006, extensively drug-resistant tuberculosis (XDR-TB) emerged. XDR-TB is defined as MDR-TB plus resistance to any fluoroquinolone and at least one injectable agent: kanamycin, amikacin or capreomycin. The spread of XDR-TB globally has been fuelled by the HIV epidemic, inadequate public health systems, limited access to high-quality laboratory resources, and a neglect of infection control measures.


[Editor's Note]: Tibotec Therapeutic's experimental agent TMC207 has shown promising activity against multidrug-resistant TB in a recent study.

8/18/09

Source
D Gaffney. New Drug-resistant TB Strains Could Become Widespread, Says New Study. Science Daily (www.ScienceDaily.com). August 12, 2009. (Adapted from materials provided by University of New South Wales.)

Reference
F Luciania, SA Sisson, H Jiangb, and others. The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences (PNAS). August 13, 2009 [Epub before print]. (Abstract).


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Protease Inhibitors
Agenerase (amprenavir)
Aptivus
(tipranavir)
Crixivan
(indinavir)
Invirase
(saquinavir hard gel)
Kaletra
(lopinavir/ritonavir)
Lexiva
(fosamprenavir)
Norvir
(ritonavir)
Prezista
(darunavir)
Reyataz
(atazanavir)
Viracept
(nelfinavir)
Nucleoside / Nucleotide Reverse
Transcriptase Inhibitors
Combivir (zidovudine/lamivudine)
Epivir (lamivudine; 3TC)
Emtriva (emtricitabine; FTC)
Epzicom (abacavir + lamivudine)
Retrovir (zidovudine; AZT)
Trizivir (abacavir + zidovudine +lamivudine)
Truvada  (tenofovir / emtricitabine)
Videx (didanosine; ddI)
Viread (tenofovir)
Zerit (stavudine; d4T)
Ziagen (abacavir)
non Nucleoside Reverse
Transcriptase Inhibitors
Etravirine (Intelence; TMC125)
Rescriptor (delavirdine)
Sustiva (efavirenz)
Viramune (nevirapine)
Entry Inhibitors
(including Fusion Inhibitors)
Fuzeon (enfuvirtide, T-20)
Selzentry
(maraviroc)
Fixed Dose Combinations
Atripla (efavirenz + emtricitabine + tenofovir)
Combivir (zidovudine + lamivudine)
Trizivir (abacavir + zidovudine + lamivudine)
Truvada (tenofovir + emtricitabine)
Integrase Inhibitor
Isentress (raltegravir)